We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Abbott Diagnostics

Download Mobile App




Image: Imperial College Begins Immunizing Hundreds of People with Experimental COVID-19 Vaccine in Early Trial (Photo courtesy of Imperial College London)

Imperial College Begins Immunizing Hundreds of People with Experimental COVID-19 Vaccine in Early Trial

Scientists at the Imperial College London (London, UK) are immunizing hundreds of people with their experimental coronavirus vaccine in an early trial after a small number of volunteers who had been vaccinated did not show any worrying safety problems. More...
04 Aug 2020
Image: COVID-19 Vaccine Could Give Immunity for At Least 12 Months, Says AstraZeneca (Photo courtesy of AstraZeneca)

COVID-19 Vaccine Could Give Immunity for At Least 12 Months, Says AstraZeneca

The COVID-19 vaccine could give immunity from the coronavirus for at least 12 months or even provide two years of protection, according to the chief behind AstraZeneca’s (Cambridgeshire, England) trial. More...
04 Aug 2020
Illustration

Rapid COVID-19 Test Uses Graphene-Enhanced Sensor to Produce Signal After Positively Identifying Viral Antigens

A new COVID-19 rapid test delivers accurate and reliable results in seconds using a graphene-enhanced sensor that produces a signal when exposed to COVID-19 viral antigens. More...
04 Aug 2020
Image: Researchers Testing Do-It-Yourself COVID-19 Vaccine on Themselves (Photo courtesy of RaDVaC)

Researchers Testing Do-It-Yourself COVID-19 Vaccine on Themselves

A group of researchers have formed the Rapid Deployment Vaccine Collaborative (RaDVaC), developed their own do-it-yourself COVID-19 vaccine and begun testing the vaccine on themselves. More...
04 Aug 2020
Image: Eli Lilly Begins Phase 3 Trial of Human Antibody LY-CoV555 for Prevention of COVID-19 (Photo courtesy of Eli Lilly and Company)

Eli Lilly Begins Phase 3 Trial of Human Antibody LY-CoV555 for Prevention of COVID-19

Eli Lilly and Company (Indianapolis, Ind, USA) has initiated BLAZE-2, a Phase 3 trial studying LY-CoV555 for the prevention of SARS-CoV-2 infection and COVID-19 in residents and staff at long-term care facilities in the US. More...
04 Aug 2020
Illustration

First FDA EUA COVID-19 Saliva Testing Kits Launched

The first FDA Emergency Use Authorization (EUA) COVID-19 saliva testing kits have been launched in the US by Accumen Inc. (Phoenix, AZ, USA) in partnership with Spectrum Solutions (Salt Lake City, UT, USA). More...
04 Aug 2020
Illustration

Pfizer and BioNTech to Supply Japan with 120 Million Doses of mRNA-Based COVID-19 Vaccine

Pfizer Inc. (New York, NY, USA) and Biopharmaceutical New Technologies (BioNTech Mainz, Germany) have entered into an agreement with Japan to supply 120 million doses of its BNT162 mRNA-based vaccine candidate against SARS-CoV2. More...
04 Aug 2020
Copyright © 2000-2020 Globetech Media. All rights reserved.